The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! About 1.33 million shares traded hands or 1049.66% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 19.28% since April 20, 2016 and is uptrending. It has outperformed by 14.73% the S&P500.
The move comes after 5 months positive chart setup for the $97.40M company. It was reported on Nov, 22 by Barchart.com. We have $3.13 PT which if reached, will make NASDAQ:FATE worth $5.84M more.
Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage
Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated it with “Outperform” rating and $4 target price in Tuesday, April 12 report. The stock has “Buy” rating given by Roth Capital on Thursday, September 22. The rating was maintained by Wedbush on Tuesday, November 8 with “Outperform”. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Buy” rating given on Thursday, September 22 by TH Capital. Raymond James initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Tuesday, October 6. Raymond James has “Outperform” rating and $8 price target.
According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.26, from 0.56 in 2016Q1. The ratio improved, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.
Geode Capital Mgmt Ltd Liability Co has 0% invested in the company for 108,029 shares. Tocqueville Asset Lp accumulated 22,000 shares or 0% of the stock. Da Davidson & holds 720 shares or 0% of its portfolio. The Pennsylvania-based Nationwide Fund Advsrs has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Bancorporation Of America De last reported 0% of its portfolio in the stock. Wells Fargo & Com Mn accumulated 1,000 shares or 0% of the stock. Kingdon Capital Mngmt Limited holds 2.26M shares or 0.21% of its portfolio. Bridgeway Mngmt accumulated 394,537 shares or 0.01% of the stock. Deutsche Bank & Trust Ag has 17,792 shares for 0% of their US portfolio. The Pennsylvania-based Vanguard Grp Inc has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Franklin Inc owns 500,000 shares or 0% of their US portfolio. The New Jersey-based Blackrock Limited Co has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Tfs Ltd Liability Company owns 20,925 shares or 0.01% of their US portfolio. Goldman Sachs Group Inc has 35,966 shares for 0% of their US portfolio. Renaissance Technology Ltd has 0% invested in the company for 180,700 shares.
More news for Fate Therapeutics Inc (NASDAQ:FATE) were recently published by: Medgadget.com, which released: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment …” on November 21, 2016. 247Wallst.com‘s article titled: “Could This Be a Turning Point for Fate Therapeutics?” and published on June 20, 2016 is yet another important article.
FATE Company Profile
Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.